Boston Therapeutics, Inc. (OTCQB: BTHE)
BTHE reported that it has closed the final tranche of approximately $1.8 million to bring total gross proceeds of approximately $5.3 million from the private placement of Common Stock and warrants to existing and new accredited investors.
Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable therapeutic compound designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.
The first goal in the management of diabetes is to slow down the absorption of glucose from the intestinal tract to reduce after-meal elevations in blood sugar. The majority of glucose in the body is derived from carbohydrates.
The body responds to the rise in blood glucose levels after meals by secreting insulin. Insulin lowers blood glucose by increasing the rate that glucose is taken up by cells throughout the body. Repeated spikes in after-meal blood sugar levels greatly stress blood sugar control and contribute to loss of sensitivity to insulin. As a result, blood sugar levels can become persistently elevated.
In people with diabetes, elevations of blood glucose levels after a meal can cause serious problems. Research indicates that an elevation in postprandial (after meal) blood sugar levels is perhaps the major contributor to the development of diabetic complications, especially heart disease and diseases of the small blood vessels within the eye, kidneys, and nerves.
BTHE 's PAZ320 is the first compound in a new class of therapies for this disease.
BTHE last trade on Friday’s activity was at $1.10, up $0.38 or 52.78%, with a volume of 160,747 shares.
BTHE is a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs.
BTHE 's product pipeline is focused on developing and commercializing therapeutic molecules for Type 2 diabetes, including: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN(TM), an injectable anti-necrosis-drug specifically designed to treat lower limb ischemia associated with diabetes.
More about Boston Therapeutics, Inc. (OTCQB: BTHE) at www.bostonti.com .
********************************
Full disclaimer at http://pennyomega.com/disclaimer
